Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]

This article refers to:

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Int J Chron Obstruct Pulmon Dis. 2013;8:501–508.

On page 501, note that in the Results section of the Abstract, the sentence “Trough FEV₁ at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively.” should read “Trough FEV₁ at week 4 for QVA149 and IND+GLY was 1.5 L ± 0.02.”

On page 505, note that the sentence “The least squares mean ± standard error (LSM ± SE) trough FEV₁ at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 and 1.5 L ± 0.18, respectively (Figure 3).” should read “The least squares mean ± standard error (LSM ± SE) trough FEV₁ at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 (Figure 3).”

Figure 3 Trough FEV₁ (L) at week 4.

Abbreviations: IND+GLY, indacaterol and glycopyrronium; FEV₁, forced expiratory volume in 1 second; CI, confidence interval.

On page 505, note that the confidence interval for Figure 3 was incorrect, and the confidence intervals and y-axis for

Figure 4 were also incorrect. The full and correct figures are given here.

Figure 4 FEV₁ AUC_{0–4 hours} at day 1 and week 4.

Abbreviations: FEV₁, forced expiratory volume in 1 second; AUC, area under curve; IND+GLY, indacaterol and glycopyrronium; CI, confidence interval.